Articles producció científica> Ciències Mèdiques Bàsiques

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values

  • Identification data

    Identifier: imarina:5133296
    Authors:
    Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen Y, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez G, Guarro J, Johnson E, Kus J, Lass-Flörl C, Linares-Sicilia M, Martín-Mazuelos E, Negri C, Pfaller M, Tortorano A
    Abstract:
    Estimating epidemiological cutoff endpoints (ECVs/ECOFFS) may be hindered by the overlap of MICs for mutant and nonmutant strains (strains harboring or not harboring mutations, respectively). Posaconazole MIC distributions for the Aspergillus fumigatus species complex were collected from 26 laboratories (in Australia, Canada, Europe, India, South and North America, and Taiwan) and published studies. Distributions that fulfilled CLSI criteria were pooled and ECVs were estimated. The sensitivity of three ECV analytical techniques (the ECOFFinder, normalized resistance interpretation [NRI], derivatization methods) to the inclusion of MICs for mutants was examined for three susceptibility testing methods (the CLSI, EUCAST, and Etest methods). The totals of posaconazole MICs for nonmutant isolates (isolates with no known cyp51A mutations) and mutant A. fumigatus isolates were as follows: by the CLSI method, 2,223 and 274, respectively; by the EUCAST method, 556 and 52, respectively; and by Etest, 1,365 and 29, respectively. MICs for 381 isolates with unknown mutational status were also evaluated with the Sensititre YeastOne system (SYO). We observed an overlap in posaconazole MICs among nonmutants and cyp51A mutants. At the commonly chosen percentage of the modeled wild-type population (97.5%), almost all ECVs remained the same when the MICs for nonmutant and mutant distributions were merged: ECOFFinder ECVs, 0.5 μg/ml for the CLSI method and 0.25 μg/ml for the EUCAST method and Etest; NRI ECVs, 0.5 μg/ml for all three methods. However, the ECOFFinder ECV for 95% of the nonmutant population by the CLSI method was 0.25 μg/ml. The tentative ECOFFinder ECV with SYO was 0.06 μg/ml (data from 3/8 laboratories). Derivatization ECVs with or without mutant inclusion were either 0.25
  • Others:

    Author, as appears in the article.: Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F, Bustamante B, Chen Y, Chakrabarti A, Chowdhary A, Chryssanthou E, Córdoba S, Gonzalez G, Guarro J, Johnson E, Kus J, Lass-Flörl C, Linares-Sicilia M, Martín-Mazuelos E, Negri C, Pfaller M, Tortorano A
    Department: Ciències Mèdiques Bàsiques
    URV's Author/s: Guarro Artigas, Josep
    Keywords: Wild type Triazole resistance Syo Posaconazole Eucast ecvs Etest Ecvs Cyp51a mutants Clsi ecvs Aspergillus fumigatus triazole resistance syo posaconazole eucast ecvs etest ecvs cyp51a mutants clsi ecvs aspergillus fumigatus
    Abstract: Estimating epidemiological cutoff endpoints (ECVs/ECOFFS) may be hindered by the overlap of MICs for mutant and nonmutant strains (strains harboring or not harboring mutations, respectively). Posaconazole MIC distributions for the Aspergillus fumigatus species complex were collected from 26 laboratories (in Australia, Canada, Europe, India, South and North America, and Taiwan) and published studies. Distributions that fulfilled CLSI criteria were pooled and ECVs were estimated. The sensitivity of three ECV analytical techniques (the ECOFFinder, normalized resistance interpretation [NRI], derivatization methods) to the inclusion of MICs for mutants was examined for three susceptibility testing methods (the CLSI, EUCAST, and Etest methods). The totals of posaconazole MICs for nonmutant isolates (isolates with no known cyp51A mutations) and mutant A. fumigatus isolates were as follows: by the CLSI method, 2,223 and 274, respectively; by the EUCAST method, 556 and 52, respectively; and by Etest, 1,365 and 29, respectively. MICs for 381 isolates with unknown mutational status were also evaluated with the Sensititre YeastOne system (SYO). We observed an overlap in posaconazole MICs among nonmutants and cyp51A mutants. At the commonly chosen percentage of the modeled wild-type population (97.5%), almost all ECVs remained the same when the MICs for nonmutant and mutant distributions were merged: ECOFFinder ECVs, 0.5 μg/ml for the CLSI method and 0.25 μg/ml for the EUCAST method and Etest; NRI ECVs, 0.5 μg/ml for all three methods. However, the ECOFFinder ECV for 95% of the nonmutant population by the CLSI method was 0.25 μg/ml. The tentative ECOFFinder ECV with SYO was 0.06 μg/ml (data from 3/8 laboratories). Derivatization ECVs with or without mutant inclusion were either 0.25 μg/ml (CLSI, EUCAST, Etest) or 0.06 μg/ml (SYO). It appears that ECV analytical techniques may not be vulnerable to overlap between presumptive wild-type isolates and cyp51A mutants when up to 11.6% of the estimated wild-type population includes mutants.
    Thematic Areas: Saúde coletiva Química Pharmacology (medical) Pharmacology & pharmacy Pharmacology Odontología Nutrição Microbiology Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Matemática / probabilidade e estatística Interdisciplinar Infectious diseases Farmacia Ensino Engenharias iv Engenharias iii Engenharias ii Enfermagem Educação física Educação Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Ciência de alimentos Biotecnología Biodiversidade Astronomia / física
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00664804
    Author's mail: josep.guarro@urv.cat
    Author identifier: 0000-0002-7839-7568
    Record's date: 2024-07-20
    Papper version: info:eu-repo/semantics/acceptedVersion
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Antimicrobial Agents And Chemotherapy. 62 (4):
    APA: Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Dannaoui E, Garcia-Effron G, Guinea J, Kidd S, Pelaez T, Sanguinetti M, Meletiadis J, Botterel F (2018). Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values. Antimicrobial Agents And Chemotherapy, 62(4), -. DOI: 10.1128/AAC.01916-17
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications
  • Keywords:

    Infectious Diseases,Microbiology,Pharmacology,Pharmacology & Pharmacy,Pharmacology (Medical)
    Wild type
    Triazole resistance
    Syo
    Posaconazole
    Eucast ecvs
    Etest
    Ecvs
    Cyp51a mutants
    Clsi ecvs
    Aspergillus fumigatus
    triazole resistance
    syo
    posaconazole
    eucast ecvs
    etest
    ecvs
    cyp51a mutants
    clsi ecvs
    aspergillus fumigatus
    Saúde coletiva
    Química
    Pharmacology (medical)
    Pharmacology & pharmacy
    Pharmacology
    Odontología
    Nutrição
    Microbiology
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Materiais
    Matemática / probabilidade e estatística
    Interdisciplinar
    Infectious diseases
    Farmacia
    Ensino
    Engenharias iv
    Engenharias iii
    Engenharias ii
    Enfermagem
    Educação física
    Educação
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciências agrárias i
    Ciência de alimentos
    Biotecnología
    Biodiversidade
    Astronomia / física
  • Documents:

  • Cerca a google

    Search to google scholar